PBK/TOPK expression in non‐small‐cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression

The aim of this study was to evaluate the prevalence of PBK/TOPK (PDZ‐binding kinase/T‐LAK cell‐originated protein kinase) expression, and explore the prognostic significance of PBK/TOPK expression alone and in combination with Ki67 and p53 expression in non‐small‐cell lung cancer (NSCLC).

[1]  B. Erler,et al.  CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma , 2011, Tumor Biology.

[2]  R. O'Connor,et al.  PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response , 2007, Oncogene.

[3]  Tadashi Imai,et al.  Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. , 2006, The Annals of thoracic surgery.

[4]  L. Mazzucchelli,et al.  Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients , 2009, British Journal of Cancer.

[5]  J. Toretsky,et al.  PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. , 2001, Blood cells, molecules & diseases.

[6]  K. Fukuchi,et al.  Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. , 2012, Lung cancer.

[7]  A. Rapoport,et al.  Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53. , 2007, Biochemical and biophysical research communications.

[8]  Yusuke Nakamura,et al.  PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. , 2006, Cancer research.

[9]  Wafik S El-Deiry,et al.  P53 and radiation responses , 2003, Oncogene.

[10]  T. Chou,et al.  Overexpression of T‐LAK cell‐originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma , 2012, Cancer science.

[11]  E. Álava,et al.  Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target , 2009, British Journal of Cancer.

[12]  Weiya Ma,et al.  Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. , 2007, Gastroenterology.

[13]  Y. Abe,et al.  Cloning and Expression of a Novel MAPKK-like Protein Kinase, Lymphokine-activated Killer T-cell-originated Protein Kinase, Specifically Expressed in the Testis and Activated Lymphoid Cells* , 2000, The Journal of Biological Chemistry.

[14]  K. Ying,et al.  PDZ-binding kinase participates in spermatogenesis. , 2001, The international journal of biochemistry & cell biology.

[15]  Christine E. Canman,et al.  P53, cell cycle control and apoptosis: Implications for cancer , 1995, Cancer and Metastasis Reviews.

[16]  C. Kang,et al.  The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. , 2008, The Annals of thoracic surgery.

[17]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[18]  P. Hainaut,et al.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. , 2005, Cancer research.

[19]  E. Paci,et al.  Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. , 2006, American journal of clinical pathology.

[20]  T. Płusa,et al.  Telomerase activity and serum levels of p53 protein as prognostic factors of survival in patients with advanced non-small cell lung cancer. , 2010, Respiratory medicine.

[21]  M. Hsiao,et al.  TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer , 2012, Oncogene.

[22]  Zhenqiu Liu,et al.  PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21 , 2010, Oncogene.

[23]  J. Verdebout,et al.  Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53 , 2003, European Respiratory Journal.

[24]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[25]  Ji-shuai Zhang,et al.  T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of Prx1 at Ser-32 Prevents UVB-induced Apoptosis in RPMI7951 Melanoma Cells through the Regulation of Prx1 Peroxidase Activity* , 2010, The Journal of Biological Chemistry.

[26]  Yeon-Hee Park,et al.  Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer , 2006, Journal of Korean medical science.

[27]  Yong-Yeon Cho,et al.  Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. , 2012, Cancer research.

[28]  J. Karp,et al.  Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. , 2004, Blood cells, molecules & diseases.

[29]  D. Branton,et al.  Characterization of PDZ-binding kinase, a mitotic kinase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[31]  A. Piotrowska,et al.  Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. , 2011, Anticancer research.

[32]  Y. Abe,et al.  A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. , 2007, Journal of molecular biology.

[33]  V. N. Nguyen,et al.  Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. , 2000, Acta histochemica.

[34]  D. Geschwind,et al.  PBK/TOPK, a Proliferating Neural Progenitor-Specific Mitogen-Activated Protein Kinase Kinase , 2005, The Journal of Neuroscience.

[35]  Günther Richter,et al.  Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  K. Sabapathy,et al.  Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore , 2010, BMC Cancer.

[37]  L. Harsan,et al.  Assessment of In Vivo Chemotherapy‐Induced DNA Damage in a p53‐Mutated Rat Tumor by Micronuclei Assay , 2003, Annals of the New York Academy of Sciences.